6 pm, 20th September 2012
Chemistry Centre, Burlington House, London
The nature of drug discovery is changing, but the UK remains a world leader in the development of new medicines. The discovery of Abiraterone is one recent success, developed at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital (RMH). In 2011, it completed its journey from an idea to a life-extending treatment for men with advanced prostate cancer.
Keynote speaker: Professor Johann de Bono, Institute of Cancer Research
Professor de Bono led on the drug’s development, taking it from Phase I first-in-man trials to the successful completion of Phase III trials. During his lecture he will highlight the Institute of Cancer Research’s unique partnership with the Royal Marsden hospital, with an emphasis on the bench-to-bedside approach that has already made a real impact on cancer patients’ lives. Professor de Bono’s talk will be followed by a chaired panel discussion which will address the question:
How can discovery programmes such as the successful work that led to the discovery of Abiraterone be repeated within the UK academic environment?
The evening will finish with a wine reception. This event is free to attend, but delegates must pre-register to guarantee admittance. Further details and online registration can be found at www.rsc.org/discovery-of-abiraterone
